KODIAK SCIENCES INC. Earnings Per Share, Basic and Diluted
KODIAK SCIENCES INC. (KOD) reported Earnings Per Share, Basic and Diluted of -$1.83 per share for the 3-month period ending 2022-03-31, per its 10-Q filed 2022-05-10.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-05-10
- KODIAK SCIENCES INC. earnings per share, basic and diluted for the quarter ending 2022-03-31 was -$1.83.
- KODIAK SCIENCES INC. earnings per share, basic and diluted for the quarter ending 2021-12-31 was -$1.79.
- KODIAK SCIENCES INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$1.30.
- KODIAK SCIENCES INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$1.08.
- KODIAK SCIENCES INC. earnings per share, basic and diluted for fiscal 2021 was -$5.16.
- KODIAK SCIENCES INC. earnings per share, basic and diluted for fiscal 2020 was -$2.91.
- KODIAK SCIENCES INC. earnings per share, basic and diluted for fiscal 2019 was -$1.25.
- KODIAK SCIENCES INC. earnings per share, basic and diluted for fiscal 2018 was -$2.77.
| Period end | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|
| 2022-03-31 | -$1.83 10-Q · filed 2022-05-10 | |||
| 2021-12-31 | -$1.79 10-K · filed 2022-03-01 | -$5.16 10-K · filed 2022-03-01 | ||
| 2021-09-30 | -$1.30 10-K · filed 2022-03-01 | -$3.36 10-Q · filed 2021-11-09 | ||
| 2021-06-30 | -$1.08 10-K · filed 2022-03-01 | -$2.06 10-Q · filed 2021-08-09 | ||
| 2021-03-31 | -$0.98 10-Q · filed 2022-05-10 | |||
| 2020-12-31 | -$0.97 10-K · filed 2022-03-01 | -$2.91 10-K · filed 2022-03-01 | ||
| 2020-09-30 | -$0.80 10-K · filed 2022-03-01 | -$1.92 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | -$0.58 10-K · filed 2022-03-01 | -$1.12 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$0.54 10-K · filed 2022-03-01 | |||
| 2019-12-31 | -$0.40 10-K · filed 2021-03-01 | -$1.25 10-K · filed 2022-03-01 | ||
| 2019-09-30 | -$0.33 10-K · filed 2021-03-01 | -$0.85 10-Q · filed 2020-11-09 | ||
| 2019-06-30 | -$0.31 10-K · filed 2021-03-01 | -$0.52 10-Q · filed 2020-08-10 | ||
| 2019-03-31 | -$0.21 10-K · filed 2021-03-01 | -$0.61 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$1.22 derived: net income ÷ weighted average shares · filed 2021-03-01 | |
| 2018-12-31 | -$0.40 10-K · filed 2020-03-16 | -$1.13 derived: net income ÷ weighted average shares · filed 2021-03-01 | -$2.77 10-K · filed 2021-03-01 | |
| 2018-09-30 | -$1.33 10-K · filed 2020-03-16 | -$3.45 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | -$0.96 10-K · filed 2020-03-16 | -$2.11 10-Q · filed 2019-08-14 | ||
| 2018-03-31 | -$1.16 10-K · filed 2020-03-16 | -$2.68 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$3.29 derived: net income ÷ weighted average shares · filed 2020-03-16 | |
| 2017-12-31 | -$1.52 10-K · filed 2019-03-27 | -$2.13 derived: net income ÷ weighted average shares · filed 2020-03-16 | -$3.72 10-K · filed 2020-03-16 | |
| 2017-09-30 | -$0.61 10-K · filed 2019-03-27 | -$2.19 10-Q · filed 2018-11-16 | ||
| 2017-06-30 | -$0.90 10-K · filed 2019-03-27 | |||
| 2017-03-31 | -$0.68 10-K · filed 2019-03-27 | |||
| 2016-12-31 | -$2.38 10-K · filed 2019-03-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |